JAP12 Rec'd PCT/PTO 29 AUG 2007

Docket No. 270423US0X PCT

IN RE APPLICATION OF: Marc ELO SERIAL NO: 10/530.712

November 8, 2005

RECOMBINANT ADENOVIRAL VECTORS AND APPLICATIONS THEREOF

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

FILED:

FOR:

Transmitted herewith is an Amendment in the above-identified application.

- □ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- Additional documents filed herewith: Request for Extension of Time (Three months), FL Graham, et al., "Adenovirus Vectors in Gene Therapy", Encyclopedia of Life Sciences, 2007 (pp 1-6)

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE			CALCULATIONS
TOTAL	39	MINUS	29	10	x	\$50	=	\$500.00
INDEPENDENT	3	MINUS	3	0	х	\$200	=	\$0.00
APPLICATION SIZE		MINUS	100	0 (each addtl. 50 sheets)	х	\$250	=	\$0.00
		☐ MULTIPLE DEPENDENT CLAIMS + \$360 =					\$0.00	
		TOTAL OF ABOVE CALCULATIONS					\$500.00	
		☐ Reduction	☐ Reduction by 50% for filing by Small Entity					\$0.00
						тот	`AL	\$500.00

- ☐ A check in the amount of \$0.00 is attached.
- Credit card payment form is attached to cover the fees in the amount of \$1.520.00
- Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

08/30/2007 GFREY1 00000132 10530712

01 FC:1615

500,00 DP

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 45,394

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Thomas M. Cunningham, Ph.D.